Modality
Bispecific Ab
MOA
BTKi
Target
TYK2
Pathway
Lipid Met
MCC
Development Pipeline
Preclinical
~Apr 2022
→ ~Jul 2023
Phase 1
~Oct 2023
→ ~Jan 2025
Phase 2
Apr 2025
→ Oct 2031
Phase 2Current
NCT04877589
894 pts·MCC
2025-04→2031-10·Recruiting
894 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2031-10-065.5y awayPh2 Data· MCC
Trial Timeline
Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3Q4
P2
Recruit…
Catalysts
Ph2 Data
2031-10-06 · 5.5y away
MCC
Recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04877589 | Phase 2 | MCC | Recruiting | 894 | Biomarker |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Voxacilimab | Pfizer | Phase 2 | TYK2 | |
| MRK-3732 | Merck & Co | Phase 1 | TYK2 | |
| AZN-8281 | AstraZeneca | Phase 1 | SHP2 | |
| BMY-3371 | Bristol-Myers Squibb | Phase 3 | WRN | |
| NVO-7872 | Novo Nordisk | NDA/BLA | B7-H3 | |
| NVO-6275 | Novo Nordisk | Phase 1 | SMN2 | |
| Zanumavacamten | GSK | Phase 2/3 | TROP-2 | |
| TAK-2403 | Takeda | Phase 2 | WEE1 | |
| Lisorapivir | Takeda | Preclinical | WRN | |
| Ivosotorasib | Vertex Pharma | Preclinical | CD38 |